FDA-Drug2018-11-21Class III
ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial, Rx only, Manufactured by: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, Branchburg, NJ 08876 USA. NDC: 66733-958-23
Eli Lilly & Co
Hazard
Labeling: Missing label; potential for missing primary container label on the vial.
Sold states
AL, AZ, CA, KS, LA, MS, OH, OR, TN, TX and Puerto Rico
Affected count
9,380 vials
Manufactured in
1 Lilly Corporate Ctr, Indianapolis, IN, United States
Products
ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial, Rx only, Manufactured by: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, Branchburg, NJ 08876 USA. NDC: 66733-958-23
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0248-2019Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief